Combination of clinical and molecular predictors to create a novel bio-clinical score that predicts outcome in relapsed/refractory diffuse large B-cell lymphoma

Relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL)

Bio-clinical model

for **event-free (EF)** and **overall surivival (OS)** of rrDLBCL patients

Clinical predictors
- Primary refractory disease
- Elevated serum LDH at relapse

Molecular predictors
- MYC expression
- BLC2 expression

Analyses

91 Immunohistochemistry (IHC)

97 Digital gene expression profiling (GEP)

67 Fluorescence in situ hybridization (FISH)

GEP and IHC cases
Total   MYC=79, BCL2=79

Digital GEP   IHC

18 20 4
   59
0   8
   0

FISH

GEP and FISH cases
Total   MYC=55, BCL2=57

IHC and FISH cases
Total   MYC=59, BCL2=61

Multivariate analysis: 3-year EFS rate

MYC, BLC2	Bio-clinical score	
	0-1 (Low Risk)	2-4 (High Risk)
IHC	55%	16%
Digital GEP	46%	5%
FISH	42%	21%

Bosch *et al.*, Haematologica, 2018